‹ All Posts
Ishwar Kathed

8 mins ago · SEBI Registration INH000024374

Alembic Pharma Secures USFDA Approval for Binimetinib

Regulatory Approval | Pharmaceutical Sector Alembic Pharmaceuticals has secured final USFDA approval for its Binimetinib Tablets (15 mg and 45 mg), strengthening its oncology generics portfolio and opening an opportunity in a sizeable US market. Key Highlights Approval received for ANDA covering 15 mg and 45 mg tablets. Generic equivalent of Mektovi, marketed by Array BioPharma. Alembic was among the first applicants for 15 mg and the sole first applicant for 45 mg with Paragraph IV certification. Eligible for 180 days of generic drug exclusivity for both strengths. Estimated US market size: $282 million for the 12 months ended September 2026 (IQVIA). Total USFDA ANDA approvals: 248, including 230 final and 18 tentative approvals. SWOT Analysis Strengths: USFDA approval, potential 180-day exclusivity and established regulatory capabilities. Weaknesses: Commercial success depends on product launch, pricing and market penetration. Opportunities: Access to a sizeable oncology market and potential revenue contribution from generic competition. Threats: Pricing pressure, competition after exclusivity and regulatory or supply-chain challenges. Investor View The approval is a positive development for Alembic Pharmaceuticals. The potential 180-day exclusivity period and estimated $282 million market provide an attractive commercial opportunity. However, actual financial benefits will depend on launch timing, competition, pricing and market share. What to Watch Next: Product launch, US market entry, sales contribution and exclusivity-related developments. Overall Outlook: Positive business development for Alembic's US generics portfolio. Disclaimer: For educational purposes only. Not a buy/sell recommendation.

#StockInNews#EquityResearch